日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Efficacy and Safety of Continuing Next-Generation ALK TKIs With Chemotherapy for Advanced ALK-Positive NSCLC: A Multicenter Retrospective Study

晚期ALK阳性非小细胞肺癌患者继续接受新一代ALK TKI联合化疗的疗效和安全性:一项多中心回顾性研究

Waliany, Sarah; Roy, Shambo Guha; Pecci, Federica; Weber, Urs M; Sun, Fangdi; Arter, Zhaohui; Lomibao, Meghanne; Alessi, Joao V; Nishino, Mizuki; Luo, Faustine; Repetto, Matteo; Falcon, Christina; Do, Andrew; Peterson, Jennifer; Liang, Joyce; Liu, Audrey; Nagasaka, Misako; Ricciuti, Biagio; Drilon, Alexander; Ou, S Ignatius; Neal, Joel W; Patil, Tejas; Awad, Mark; Yeap, Beow Y; Digumarthy, Subba R; Lin, Jessica J

Breast carcinomas associated with microglandular adenosis are linked to germline alterations in homologous recombination-deficiency genes

与微腺病相关的乳腺癌与同源重组缺陷基因的种系改变有关

Schwartz, Christopher J; Genco, Iskender; Repetto, Matteo; Muldoon, Daniel; Gazzo, Andrea; Terraf, Panieh; Grabenstetter, Anne; Ross, Dara; Zhang, Hong; Mandelker, Diana; Powell, Simon; Weigelt, Britta; Bandlamudi, Chaitanya; Brogi, Edi; Pareja, Fresia; Wen, Hannah Y

Genomic landscape of breast cancer in elderly patients

老年乳腺癌患者的基因组图谱

Selenica, Pier; Dopeso, Higinio; Repetto, Matteo; Basili, Thais; Gazzo, Andrea M; Schwartz, Christopher J; Derakhshan, Fatemeh; Marra, Antonio; Ferrando, Lorenzo; Beets-Tan, Regina G H; Wen, Y H; Ross, Dara S; Brogi, Edi; Zhang, Hong; Norton, Larry; Chandarlapaty, Sarat; Razavi, Pedram; Mandelker, Diana; Reis-Fiho, Jorge S; Weigelt, Britta; Pareja, Fresia

Responsiveness of different MET tumour alterations to type I and type II MET inhibitors.

不同MET肿瘤改变对I型和II型MET抑制剂的反应性

Murciano-Goroff Yonina R, Foglizzo Valentina, Chang Jason, Rekhtman Natasha, Sisk Ann Elizabeth, Gibson Jamie, Judka Lia, Clemens Kristen, Roa Paola, Ahmed Shaza Sayed, Bremer Nicole V, Binaco Courtney Lynn, Muzungu Sherifah Kemigisha, Rodriguez Estelamari, Merrill Madeline, Sgroe Erica, Repetto Matteo, Stadler Zsofia K, Berger Michael F, Yu Helena A, Toska Eneda, Kannan Srinivasaraghavan, Verma Chandra S, Drilon Alexander, Cocco Emiliano

Targeting ROS1 rearrangements in non-small cell lung cancer: Current insights and future directions

靶向非小细胞肺癌中的ROS1重排:当前认识和未来方向

Desilets, Antoine; Repetto, Matteo; Yang, Soo-Ryum; Drilon, Alexander

RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future

RET抑制剂在RET融合阳性肺癌中的应用:过去、现在和未来

Chen, Monica F; Repetto, Matteo; Wilhelm, Clare; Drilon, Alexander

Author Correction: TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers

作者更正:TKI类型转换可克服ROS1融合阳性癌症中的ROS1 L2086F突变

Thawani, Rajat; Repetto, Matteo; Keddy, Clare; Nicholson, Katelyn; Jones, Kristen; Nusser, Kevin; Beach, Catherine Z; Harada, Guilherme; Drilon, Alexander; Davare, Monika A

TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers.

TKI 类型转换可克服 ROS1 融合阳性癌症中的 ROS1 L2086F 突变

Thawani Rajat, Repetto Matteo, Keddy Clare, Nicholson Katelyn, Jones Kristen, Nusser Kevin, Beach Catherine Z, Harada Guilherme, Drilon Alexander, Davare Monika A

Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents

Zurletrectinib 是一种新一代 TRK 抑制剂,对具有靶向耐药性的 NTRK 融合阳性肿瘤具有强大的颅内活性。

Roa, Paola; Foglizzo, Valentina; Harada, Guilherme; Repetto, Matteo; Kulick, Amanda; de Stanchina, Elisa; de Marchena, Michelle; Auwardt, Supipi; Sayed Ahmed, Shaza; Bremer, Nicole Virginia; Yang, Soo-Ryum; Feng, Yangbo; Zhou, Chao; Kong, Norman; Liang, Ruixia; Xu, Haipeng; Zhang, Bin; Bardelli, Alberto; Toska, Eneda; Ventura, Andrea; Drilon, Alexander; Cocco, Emiliano

Repotrectinib: Redefining the therapeutic landscape for patients with ROS1 fusion-driven non-small cell lung cancer

瑞波替尼:重新定义ROS1融合驱动的非小细胞肺癌患者的治疗格局

Desilets, Antoine; Repetto, Matteo; Drilon, Alexander